

Clinical trials of clofibrate

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
clofibrate vs placebo			
Acheson , 1972 n=NA follow-up: 6 years	clofibrate versus placebo	cerebral vascular disease	Parallel groups NA UK
Begg , 1971 n=76/79 follow-up: 3.5 y	clofibrate versus placebo	peripheral arteriopathy	Parallel groups
CDP Clofibrate , 1975 n=1103/2789 follow-up: 6.2 years	clofibrate 1.8 mg/d versus placebo	men, 30-64 y	Parallel groups double blind USA
Cullen , 1974 n=20/20 follow-up: 2 years	clofibrate versus placebo		Parallel groups
Hanefeld , 1991 n=379/382 follow-up: 5 years	clofibric acid 1.6 g/day versus placebo	newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus	Parallel groups double-blind Germany
Harrold , 1969 n=30/33 follow-up: 1 years	clofibrate versus placebo	diabetic retinopathy	Parallel groups double-blind
Newcastle , 1971 n=244/253 follow-up: 3.6 y	clofibrate 1.5-2 g daily versus placebo	Hommes et femmes <65 ans	Parallel groups double blind UK
Scottish , 1971 n=350/367 follow-up: 3.4 years	clofibrate 1.6-2 g daily versus placebo	Hommes et femmes, de 40 69 ans	Parallel groups double blind Scotland

continued...

Trial	Treatments	Patients	Trials design and methods
VA Neurology Section , 1974 n=268/264 follow-up: 1.8 years	clofibrate versus placebo	treatment of cerebrovascular disease	Parallel groups USA
WHO clofibrate , 1978 n=5331/5296 follow-up: 5.3 years	clofibrate 1.6 g daily versus olive oil	primary prevention, Hommes, de 30 59 ans	Parallel groups double blind Scotland, Hungary, Czech Republic
colestipol+clofibrate vs placebo			
SCOR , 1990 n=48/49 follow-up: 2.0 years	colestipol (15 to 30mg/d) + clofibrate (2g/d) versus diet	patients with primary hypercholesterolemia	Parallel groups

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with LDL elevation and without CHD at <http://www.trialresultscenter.org/go-Q5>
- cholesterol lowering intervention for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q6>
- cholesterol lowering intervention for cardiovascular prevention in patients with other atherosclerotic localisation at <http://www.trialresultscenter.org/go-Q126>
- cholesterol lowering intervention for cardiovascular prevention in all chronic situations at <http://www.trialresultscenter.org/go-Q154>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

References

Acheson, 1972:

Acheson J, Hutchinson EC Controlled trial of clofibrate in cerebral vascular disease. *Atherosclerosis* 1972;15:177-83 [4579955]

Begg, 1971:

Begg TB, Rifkind BM [Evaluation of clofibrate therapy in peripheral arteriopathy] *Minerva Med* 1971;62:3469-75 [5097219]

CDP Clofibrate, 1975:

, Clofibrate and niacin in coronary heart disease. *JAMA* 1975; 231:360-81 [1088963]

Cullen, 1974:

Hanefeld, 1991:

Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. *Diabetes Care* 1991;14:308-17 [2060433]

Harrold, 1969:

Harrold BP, Marmion VJ, Gough KR A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. *Diabetes* 1969;18:285-91 [4894161]

Newcastle, 1971:

, Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. *Br Med J* 1971; 4:767-75 [4943605]

Scottish, 1971:

, Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. *Br Med J* 1971; 4:775-84 [4943606]

VA Neurology Section, 1974:

The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. *Stroke* 1973;4:684-93 [4723698]

WHO clofibrate, 1978:

, WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. *Lancet* 1984; 2:600-4 [6147641]

Heady JA, Morris JN, Oliver MF, WHO clofibrate/cholesterol trial: clarifications. *Lancet* 1992; 340:1405-6 [1360101]

SCOR, 1990:

Sepowitz AH, Smith FR, Berns L, Eder HA, Goodman DS Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia. *Atherosclerosis* 1981;39:35-43 [7018502]

Entry terms: Ethyl Chlorophenoxyisobutyrate, Atromid, Atromid S, Miscleron, Miskleron, Athromidin,